Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/00000542-197405000-00024 | DOI Listing |
Pharmacol Res
January 2025
Department of Clinical Pharmacy, Xiangtan Central Hospital (The affiliated hospital of Hunan university), Xiangtan 411100, China. Electronic address:
Pharmacol Res
January 2025
Embedded Systems and Artificial Intelligence Group, Universidad Cardenal Herrera-CEU, CEU Universities, Valencia 46115, Spain. Electronic address:
ACS Med Chem Lett
December 2024
Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
This Letter details our efforts to develop novel, non-acetylene-containing metabotropic glutamate receptor subtype 5 (mGlu) negative allosteric modulators (NAMs) with improved pharmacological properties. This endeavor involved replacing the ether-linked pyrimidine moiety, a metabolic liability, with various 5-membered heterocycles. From this exercise, we identified , a highly brain penetrant and selective mGlu NAM which displayed moderate potency against both human and rat mGlu.
View Article and Find Full Text PDFACS Med Chem Lett
December 2024
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, 1000 Ljubljana, Slovenia.
In this Letter, we present a small series of novel bacterial topoisomerase inhibitors (NTBIs) that exhibit both potent inhibition of DNA gyrase and potent antimycobacterial activity. The disclosed crystal structure of DNA gyrase in complex with DNA and compound from this NBTI series reveals the binding mode of an NBTI in the GyrA binding pocket and confirms the presence and importance of halogen bonding for the excellent on-target potency. In addition, we have shown that compound is a promising DNA gyrase inhibitor, with an IC for gyrase of 0.
View Article and Find Full Text PDFComput Methods Programs Biomed
February 2025
AdventHealth Global Robotics Institute, FL, USA; University of Central Florida (UCF), FL, USA.
Introduction: Prostate cancer remains a significant health concern, with radical prostatectomy being a common treatment approach. However, predicting postoperative functional outcomes, particularly urinary continence and erectile function, poses challenges. Emerging artificial intelligence (AI) technologies offer promise in predictive modeling.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!